43
https://pubmed.ncbi.nlm.nih.gov/38117666
The study found that adding intravitreal dexamethasone implant to anti-VEGF therapy for neovascular age-related macular degeneration patients with persistent disease activity and high treatment demand resulted in a significant increase in treatment intervals while maintaining stable central retinal thickness and visual acuity, suggesting a potential role of inflammation or steroid-responsive factors in treatment resistance.